Cidara Therapeutics, Inc.
CDTX evidence brief
What we can confirm
- Market Cap:
- $6.96B
What it means
What to watch
Prepared research question
What matters most for CDTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
Market Cap
$6.96B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 52 clinical trials for Cidara Therapeutics, Inc..
Run Cidara Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cidara Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Regulatory
Financials
Governance
Frequently asked questions
Who is the CEO of Cidara Therapeutics, Inc.?
Chief Executive Officer is the chief executive officer of Cidara Therapeutics, Inc. (CDTX).
Where is Cidara Therapeutics, Inc. headquartered?
Cidara Therapeutics, Inc. (CDTX) is headquartered in San Diego, CA, United States.
What therapeutic areas does Cidara Therapeutics, Inc. focus on?
Cidara Therapeutics, Inc. develops therapies across Oncology, Neurology, Immunology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Pain, Dermatology, Hematology, Nephrology, Musculoskeletal, Reproductive, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.